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Introduction
Nephritis is a major cause of morbidity and mortality in 
patients with lupus. Nephritis occurs in approximately 
50% of lupus patients, but rates vary signiﬁ  cantly between 
genders (men more than women) and ethnicities (more 
common in people of color). Men and minorities with 
lupus nephritis are also more likely to progress to end-
stage renal disease than women or people of European 
ancestry. Th   e multiple factors underlying these 
demographic diﬀ  erences are unclear at this time [1].
Th  e International Society of Nephrology revised the 
World Health Organization classiﬁ   cation of lupus 
nephritis recently, although maintaining six classes [2]. 
Th   e pathologic classes vary from mild mesangial involve-
ment (Class I) to diﬀ  use proliferative disease (Class IV) to 
membranous disease (Class V) to end-stage ﬁ  brosis 
(Class VI). Although most attention in lupus nephritis is 
focused on glomerular disease, there is also signiﬁ  cant 
tubular disease that impacts prognosis and renal function 
[3]. For the purposes of the present review, we will 
primarily focus on the proliferative forms of lupus 
nephritis (focal proliferative, Class III disease; and diﬀ  use 
proliferative, Class IV disease), highlighting several 
contributors to tissue injury.
Much of what is known about pathogenic factors in 
tissue damage in lupus nephritis was derived from studies 
of murine models of lupus, with conﬁ  rmation as possible 
in humans. Th  ese studies utilize multigenic models of 
lupus (that is, MRL/lpr, NZB/NZW, and NZM congenic 
strains) as well as single gene mutants (that is, DNAse 1, 
Nrf2, or Fcγ receptor (FCγR) knockouts) [4,5]. Th  ese 
models share common features of human disease such as 
anti-double-stranded DNA (anti-dsDNA) antibodies and 
proliferative nephritis, but diﬀ  er in their renal cytokine/
chemokine proﬁ   le, cellular inﬁ   ltration and acuity/
chronicity of disease [5]. Th   us, as in human disease, there 
is hetero  geneity of pathogenic mechanisms in murine 
lupus nephritis.
Autoantibodies and renal immune complex 
deposition
Th  e presence of autoantibodies is a requirement for 
develop  ment of lupus nephritis [6]. Antibodies to dsDNA/
nucleosomes are most closely linked with development of 
nephritis [7], although what separates pathogenic from 
nonpathogenic anti-dsDNA antibodies is not clear [8]. 
Pathogenic anti-dsDNA antibodies deposit as immune 
complexes (IC) [6]. When anti-C1q antibodies are 
present along with anti-dsDNA antibodies, development 
of renal disease is accelerated [9,10].
Th  ere are three postulated mechanisms for formation 
of glomerular ICs, all of which probably contribute to 
disease in some patients, given the heterogeneity of 
disease [11]. Th  e ﬁ  rst mechanism is deposition of pre-
formed serum ICs [12]. Th  is mechanism is hard to 
conﬁ  rm, as ICs are diﬃ   cult to isolate or quantify in lupus 
patient sera and thus are not felt to play a major role in 
the pathogenesis of lupus nephritis. Binding of auto-
antibodies to in situ glomerular antigens such as laminin, 
annexin II or heparin is a second mechanism postulated 
for IC deposition. Th  is crossreactivity is demonstrated 
via the elution of antibodies from glomeruli that bind 
these antigens in addition to dsDNA/chromatin [13,14].
A recent series of investigations implicates a third 
mechanism, anti-dsDNA/chromatin antibodies binding 
to nucleosomes/DNA present in the glomerular matrix, 
as the most compelling [13]. Due to charge/charge inter-
actions, circulating DNA/nucleosomes can deposit in the 
glomerular basement membrane and serve as antigen for 
autoantibodies. Another source of glomerular DNA/
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intrinsic glomerular cells [7]. Indeed, recent electron 
microscopic co-localization experiments in human and 
mouse lupus kidneys indicated that antibodies present in 
the glomerulus are bound to electron-dense deposits that 
were identiﬁ  ed to be nucleosomal material [15]. Follow-
ing the formation of these ICs, there is down  regulation of 
DNAse I in the kidney, which allows for enhanced 
amounts of nucleosomal material in the glomerulus [16]. 
Th  ese complexes can then lead to further activation of 
immune pathways by co-stimulation of FcγRs and 
endosomal Toll-like receptors (TLRs) and/or by activat-
ing the complement cascade [7]. Although the latter 
mechanism of antibodies binding nucleosomal material 
from necrotic glomerular cells provides a compelling 
story, it is likely that any of these mechanisms may be 
present in a given patient [11].
Complement and tissue injury in lupus nephritis
Complement has a dual role in lupus. Deposition of 
complement proteins in glomeruli is a key feature of 
lupus nephritis. Th  ere is strong evidence that comple-
ment activation is deleterious in lupus nephritis [17]. Th  is 
is in contrast to the known association of early comple-
ment component deﬁ   ciency with lupus. Individuals 
deﬁ   cient in C1 components, C2 and C4, have a high 
prevalence of lupus due to impaired clearance of ICs/
apoptotic bodies leading to breaking of tolerance. Activa-
tion of the classical pathway of complement activation 
thus appears protective against lupus due to enhanced 
clearance of ICs and cellular debris [18].
Recent ﬁ  ndings implicate the alternative complement 
pathway as a key component of complement-mediated 
damage in lupus nephritis [19,20]. Activation of the alter-
native complement pathway triggers an ampliﬁ  cation 
loop that accelerates cleavage of C3 to C3b, covalent 
bind  ing to cellular surfaces, with release of the anaphylo-
toxin C3a and C5a, and formation of the complement 
membrane attack complex. It is currently unclear which 
of the outcomes of complement activation are most 
important in lupus nephritis: generation of C3a and C5a 
or formation of the membrane attack complex.
Blocking the alternative complement pathway either 
genetically or pharmacologically leads to signiﬁ  cantly 
decreased severity of renal disease in murine lupus 
models [20-22]. Eliminating the natural inhibitor of the 
alternative path  way, Factor H, leads to acceleration of 
lupus-like renal disease [23]. Pharmacologic inhibition of 
the alternative pathway is eﬀ  ective in both MRL/lpr mice 
and NZM congenic mice [19,21]. Th  ese results suggest 
that the alternative complement pathway is a key 
mechanism for tissue injury in lupus nephritis. Genetic 
deletion of C3 has minimal eﬀ   ect on murine lupus 
nephritis, probably due to diminished clearance of ICs 
enhancing immune activation by noncomplement-
mediated mechanisms [24]. Blocking the C3a receptor 
has minimal impact on disease [25], while blocking 
complement activation further downstream is eﬀ  ective, 
as studies of C5aR-deﬁ   cient mice or using a C5aR 
blocking antibody also led to decreased severity of renal 
disease in murine models of lupus [26,27].
Complement may also play a role in tubular damage in 
lupus. Development of proteinuria leads to spilling of 
complement components into the urine. Complement C3 
is activated in urine via pH and urea, resulting in forma-
tion of membrane attack complexes on the epithelial side 
of tubular cells [28]. Th   ere are no complement protective 
mechanisms present on the epithelial side of renal 
tubular epithelial cells, resulting in unchecked comple-
ment activation and tubular damage. Th  ese  experiments 
were performed under adriamycin-induced proteinuria 
in mice, not in lupus, but similar mechanisms may 
explain some of the tubular damage that occurs in lupus.
Fcγ receptors and Toll-like receptors in lupus 
nephritis
Another mechanism by which ICs may lead to tissue 
damage is via activation of activating FcγRs, upon bind-
ing of immunoglobulin Fc regions by FcγR-expressing 
cells [29]. Although FcγRs are clearly implicated in the 
development of lupus in genetic studies of gain-of-
function and loss-of-function mutations and copy numbers 
of FcγR genes, their role in predisposition to lupus 
nephritis and/or tissue injury is not as clear [29-32]. In 
mice, knockout of speciﬁ  c FcγR can lead to accentuation 
or diminution of disease; most of the eﬀ  ect, however, is 
on development of lupus rather than speciﬁ  c tissue injury 
[33,34]. Any impact of FcγR on disease is highly depen-
dent on background strain [35]. Similarly, reports of asso-
ciations of FcγR genetic changes with nephritis appear 
linked to speciﬁ  c ethnicities [29].
FcγR may be important in association with TLRs in 
mediating IC-induced inﬂ  ammation in the kidney [36]. 
As noted above, dsDNA-containing ICs may activate 
kidney resident cells via a co-signaling mechanism of 
FcγR activation via the autoantibody and TLR9 activation 
via dsDNA. Th   is type of two-step activation is known to 
activate B cells by ICs containing either TLR9 or TLR7 
activators such as dsDNA or single-stranded RNA [37]. 
Inhibition of TLR7/9 is eﬀ  ective in treating murine lupus, 
although whether primarily at the level of systemic 
autoimmunity or via blocking speciﬁ   cally renal tissue 
damage is not clear [38].
Immune cells in lupus nephritis
Following the formation and/or deposition of ICs in the 
kidney, interactions between resident renal cells and 
inﬁ  ltrating  inﬂ   ammatory cells promote tissue injury. 
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duc  tion leads to further inﬂ  ux of inﬂ  ammatory cells and 
production of proinﬂ   ammatory cytokines, ultimately 
resulting in renal inﬂ  ammation, tissue injury and ﬁ  brosis. 
T cells are important mediators in both mouse models 
and human patients in the progression of lupus nephritis. 
Lupus T cells express increased levels of molecules neces-
sary for homing and/or demonstrate increased homing to 
the kidney [39-42]. Mechanisms by which T cells contri-
bute to tissue injury include activating and providing help 
to nephritogenic antibody-producing B cells, recruiting 
macrophages and dendritic cells (DCs), and producing 
cytokines. Indeed, kidney-inﬁ  ltrating T cells – including 
CD4+, CD8+ and IL17-producing CD4–CD8– double-
negative T cells – are activated and express a wide array 
of proinﬂ  ammatory cytokines [43-46]. Depleting T cells 
or blocking T-cell activation reduces progression of 
nephritis in lupus mouse models [47,48].
Pathogenic B cells have a variety of functions that 
contri  bute to lupus nephritis. Namely they produce auto-
antibodies that can cause renal damage via disruption of 
cellular functions, cytotoxicity mediated by interactions 
with complement and release of inﬂ  ammatory mediators. 
Studies in lupus mouse models demonstrated that inﬁ  l-
trat  ing B cells in the kidney secrete antibodies with 
various Ag speciﬁ  cities, contributing to increased in situ 
ICs [49-51]. Similarly, germinal center-like structures and 
T-cell–B-cell aggregates present in the kidney suggest in 
situ secretion of pathogenic antibodies, including 
nephritogenic antibodies, and ICs in human lupus 
patients [52-54]. Depleting B cells either prior to or after 
disease onset prevented and/or delayed the onset of 
nephritis in several diﬀ  erent lupus mouse models [55-58] 
and resulted in complete or partial clinical remission in 
patients [59]. MRL/lpr lupus-prone mice that have B cells 
unable to secrete antibodies still develop nephritis, 
however, although less severely [60] – indicating that 
additional B-cell functions, such as antigen presentation 
and activa  tion of pathogenic T cells and proinﬂ  ammatory 
cyto  kine production (IL-6 and TNFα), contribute signiﬁ  -
cantly to kidney injury.
Neutrophils, macrophages and DCs, present in nephritic 
kidneys, also are contributors to injury. Neutro  phils are a 
source of neutrophil extracellular traps that contain self-
antigens such as histones and DNA, and are present in 
ICs deposited in the kidney of systemic lupus erythe-
matosus (SLE) patients [61-64]. Th   e response to neutro-
phil extracellular traps contributes to kidney injury 
through the activation of plasmacytoid DCs and produc-
tion of type I interferon [63,64]. DCs and macrophages 
produce T-helper type 1 proinﬂ  ammatory  cytokines 
(IL-12 and IFNγ), express chemokine receptors and 
interact with autoreactive T  cells to recruit additional 
inﬂ   am  matory cells. Reduc  tion of CD11c+ DCs in the 
MRL/lpr lupus-prone model resulted in improved kidney 
disease [65], and the presence of plasmacytoid DCs was 
correlated with high IL-18 expression in the glomeruli of 
patients with active nephritis [66]. An activated 
macrophage population with a type II phenotype (M2b) 
that expresses high amounts of proinﬂ  ammatory 
cytokines and exhibits tissue degrada  tion is associated 
with the onset of proteinuria in NZB/NZW F1 mice [67-
69]. Similarly, in lupus patients with nephritis, 
macrophage inﬁ   ltration in the kidney correlates with 
disease [70] (reviewed in [71]).
Cytokines and chemokines
Production of cytokines and chemokines in glomeruli 
early during lupus nephritis precedes inﬂ  ammatory cell 
inﬁ  ltration and proteinuria [72,73]. T-helper type 1 cyto-
kines are predominantly present in nephritic kidneys in 
SLE patients [74,75]. T-helper type 1 proinﬂ  ammatory 
cytokines that contribute to tissue damage include IL-12, 
IL-18 and IFNγ. High IL-18 and/or IL-12 production is 
observed in glomeruli of human and mouse lupus 
nephritis. IL-18 overexpression in kidneys of predisease 
MRL/lpr lupus-prone mice resulted in accumulation of 
leukocytes in the kidney and increased renal pathology 
and proteinuria [76]. Similarly, MRL/lpr mice in which 
IL-12 was overexpressed presented increased T-cell inﬁ  l-
tra tion,  speciﬁ  cally IFNγ-producing T cells, and acceler-
ated nephritis [77], while MRL/lpr IL12–/– mice showed 
reduced IFNγ levels and delayed nephritis [78]. Higher 
IL-18, IL-12 and IFNγ levels were demonstrated in SLE 
patients compared with healthy controls, and speciﬁ  cally 
in SLE patients with nephritis compared with patients 
without nephritis. Urinary IL-12 levels correlated with 
onset and severity of nephritis in these patients [66,79]. 
Th   e major mechanism of renal injury by IL-18 and IL-12 
is probably through their upregulation of IFNγ. Th  e  levels 
of IFNγ in nephritic MRL/lpr mice are increased 
compared with controls, and kidney pathology in mice 
overexpressing IL-12 requires IFNγ [77]. Importantly, 
IFNγ signaling was demonstrated to directly induce cell 
death of tubular epithelial cells in MRL/lpr kidneys [80].
Chemokines contribute to renal damage by recruiting 
inﬂ  ammatory cells to the kidney. Proinﬂ  ammatory chemo-
kines/growth factors including monocyte chemo  attrac-
tant protein-1 (MCP-1, CCL2), macrophage inﬂ  amma-
tory protein-1β (CCL4), RANTES (CCL5), macrophage 
colony-stimulating factor and IFNγ-induced protein-10 
(CXCL10) were demonstrated to be upregulated in the 
kidney of lupus-prone mice prior to proteinuria and renal 
damage [81]. Th   eir expression was followed by 
mononuclear inﬁ   ltration and increased expression of 
their respective receptors (CCR1, CCR2 and CCR5). 
Increased levels of macrophage inﬂ  ammatory protein-1α 
(CCL3), MCP-1, RANTES and IFNγ-induced protein-10 
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Of these chemokines, MCP-1 was demonstrated to be 
associated with kidney damage in lupus. MCP-1 levels 
increase in the kidney as nephritis progresses in the 
MRL/lpr lupus model [84]. A knockout of MCP-1 on the 
MRL/lpr background resulted in reduced macrophage 
and T-cell inﬁ  ltration in the kidney, reduced proteinuria 
and renal pathology and prolonged survival [84]. 
Blockade of MCP-1 after disease onset improved renal 
disease and prolonged survival, characterized by 
decreased renal inﬁ  ltration by macro  phages and T cells 
[85,86]. In lupus nephritis patients, tubulo  interstitial 
expression of MCP-1 was demonstrated to be associated 
with chronic renal damage [75] and urinary MCP-1 levels 
were associated with renal disease activity [87,88].
Transcription factors
Th  e signal transducers and activators of transcription 
(STAT) factor family is part of the Jak/STAT signaling 
pathway activated by cytokines and contains several 
members identiﬁ  ed as playing roles in lupus nephritis, 
including STAT1 and STAT4.
STAT1, when activated, binds to IFNγ-activated 
sequences in the promoters of IFNγ-inducible genes, and 
IFNγ induced the activation of STAT1 in mesangial cells 
of MRL/lpr mice [89]. Elevated STAT1 expression, both 
total and activated forms, is present in kidneys of 
nephritic lupus mice with predominant expression in 
glomeruli [89]. In SLE patients, STAT1 expression is 
present in renal biopsies of lupus nephritis patients and 
expression levels correlated with disease activity [90].
STAT4 was identiﬁ   ed as a lupus risk gene. A poly-
morphism identiﬁ  ed in STAT4 is associated with dsDNA 
antibodies and severe nephritis in human SLE [91]. In 
NZM2410 and NZM2328 lupus-prone mouse strains, 
loss of STAT4 results in lower levels of IgG anti-dsDNA 
antibodies, but development of more severe renal disease 
[92,93].
Transcription factors such as STAT factors inﬂ  uence 
the expression of an array of genes that play a role in the 
cellular function of immune cells and/or the response of 
cells in target tissues to inﬂ  ammation, inﬂ  uencing the 
extent of tissue injury. Dysregulation of transcription in 
lupus nephritis is further indicated by the profound eﬀ  ect 
of alterations in Ets factor/Fli-1 expression and the 
impact of histone deacetylase inhibitors, which diminish 
gene transcription, on development and severity of renal 
disease.
Reactive intermediates in tissue injury
Several studies utilizing competitive inhibitors of 
inducible nitric oxide synthase (iNOS) suggest that iNOS 
activity is pathogenic in murine lupus [94,95]. Inhibiting 
iNOS activity in MRL/lpr mice, before disease onset, 
with the nonspeciﬁ  c arginine analog l-NG-monomethyl-
l-arginine reduced 3-nitrotyrosine formation in the 
kidney, partially restored renal catalase activity, and 
inhibited cellular proliferation and necrosis within the 
glomerulus [94,95]. Th   e partially selective iNOS inhibitor 
l-N6-(-iminoethyl)lysine had a similar eﬀ  ect when used 
to treat these mice prior to disease onset [96]. l-NG-
monomethyl-l-arginine therapy in NZB/W mice that 
were already suﬀ  ering from nephritis had a similar but 
less profound eﬀ   ect on proteinuria and renal histo-
pathology than did preventative therapy [97]. However, 
l-NG-monomethyl-l-arginine as monotherapy for the 
treatment of active disease was less eﬀ   ective in the 
rapidly progressive MRL/lpr model [97]. Th  ese ﬁ  ndings 
suggest that overproduction of nitric oxide is deleterious 
and mediates tissue damage in lupus nephritis.
Th   e mechanisms through which iNOS activity may be 
pathogenic in SLE were studied in animal models and in 
vitro. Peroxynitrite (ONOO–), a byproduct of iNOS 
activity, can nitrate amino acids and change the catalytic 
activity of enzymes [97]. One such enzyme, catalase, 
serves to protect host tissues from free radical attack 
[98]. In vascular tissue, prostacyclin synthase and endo-
thelial nitric oxide synthase are inactivated by per  oxy-
nitrite, leading to vasoconstriction [99]. Th  ese observa-
tions suggest that one mechanism through which iNOS 
activity is pathogenic is via deactivation of tissue 
protective enzymes. Nitrosylation is also being increas-
ingly recognized as a mechanism for impacting gene 
regulation similar to methylation and acetylation. Nitro-
sylation of NF-κB modulates its function, altering resul-
tant inﬂ  am  matory gene transcription. Such nitrosy  lation 
does not appear to impact the nuclear migration of 
NF-κB, but rather modulates its transcriptional activity 
once inside the nucleus [100]. Such nitrosylation can be 
achieved in vivo by administering S-nitrosoglutathione, 
providing a potential therapeutic pathway via modulation 
of reactive intermediates [100].
Markers of systemic nitric oxide production are 
elevated in patients with SLE in a manner that parallels 
disease activity [101]. Th   ose patients with lupus nephritis 
had the most elevated markers of systemic nitric oxide 
production among SLE subjects [102]. Th  is observation 
spawned the hypothesis that glomerular proliferative 
lesions were a source of increased nitric oxide produc-
tion, as well as a potential result of inappropriate nitric 
oxide production. Several reports supported this hypo-
thesis, with renal biopsy studies showing increased iNOS 
expression in the glomeruli of lupus nephritis subjects 
[101,103] – particularly in mesangial cells, glomerular 
epithelial cells, and inﬁ  ltrating inﬂ  ammatory cells [101]. 
When 3-nitrotyrosine was used as a surrogate for iNOS 
activity, the association with disease activity was greater 
in African Americans [104], suggesting a possible 
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reactive oxygen intermediate production versus reactive 
nitrogen intermediate production that may impact 
outcome.
To assess whether genes involved in reactive oxygen 
intermediate production are associated with lupus 
nephritis, polymorphisms in the gene for myelo  per-
oxidase were assessed. Th   ere was a signiﬁ  cant correlation 
between the low expressing myeloperoxidase 463A allele 
and the risk for developing nephritis in African 
Americans [105]. Th   is association was subsequently con-
ﬁ   rmed in two other cohorts. Th  is ﬁ   nding may seem 
paradoxical until one considers that reactive oxygen 
inter  mediates can sequester reactive nitrogen inter-
mediates and that low myeloperoxidase activity can lead 
to increased OH radical stress. Polymorphisms of iNOS 
and endothelial nitric oxide synthase are also reported to 
be associated with genetic risk of developing lupus, 
although associations with renal disease are less clear 
[106,107]. A recent study demonstrated that inhibit  ing 
reactive inter  mediate production in diabetics im  proved 
renal function, suggesting that a similar strategy may also 
be eﬀ  ective in lupus [108].
Renal regeneration/fi  brosis
End-stage renal disease in lupus is secondary to loss of 
glomerular and tubular function due to renal cell death 
and resultant ﬁ  brosis.  Th  e factors important in the 
inﬂ  ammatory process are more clearly deﬁ  ned than the 
factors resulting in progressive glomerular/tubular loss 
Figure 1. Summary of proposed pathogenic mechanisms in tissue injury in lupus nephritis. Top right: The fi  rst step leading to nephritis 
involves the production of autoantibodies to self-antigens followed by formation of immune complexes (ICs) in glomeruli. IC deposition leads 
to complement activation and intrinsic renal cell activation (mesangial cells (MC) and endothelial cells (EC)), both leading to local chemokine 
and cytokine infl  ammation. Chemokine expression leads to an infl  ux of infl  ammatory cells such as lymphocytes and macrophages. Left: Infl  ux 
of immune cells leads to interstitial as well as further glomeruli infl  ammation and EC activation. Activated renal cells (MC and podocytes) and 
infi  ltrating immune cells (macrophages and dendritic cells (DCs)) produce reactive nitrogen (nitric oxide (NO)) and reactive oxygen species (ROS). 
The combined expression of cytokines and ROS results in further renal infl  ammation and fi  brosis, resulting in cumulative tissue destruction both at 
the glomerular level (top right) and the tubular level (left). Bottom right: Lymphocyte interactions and functions such as cytokine expression and 
antibody production contribute to infl  ammation and damage in the tubules and glomeruli. BCR, B-cell receptor; FcR, Fc receptor; MCP-1, monocyte 
chemoattractant protein-1; STAT, signal transducers and activators of transcription; TCR, T-cell receptor.
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growth factor beta expression is associated with renal 
ﬁ   brosis [109]. Co-factors such as hypertension, 
production of vasoactive substances such as kallikrein, 
ongoing proteinuria and nephrotoxic drugs play an 
important role in progression of renal disease in lupus. 
Genetic factors are probably also a major determinant of 
progression to end-stage renal disease. Factors involved 
in renal regeneration post injury are even less well 
deﬁ  ned. Recruitment of stromal cells to the kidney via 
chemokine receptors and C3a may result in repair of 
some tissue damage, but further research is needed in 
this area to deﬁ  ne therapeutic strategies [110].
Conclusion
In summary, the pathogenesis of lupus nephritis and 
mechanisms of resultant renal injury remains an active 
ﬁ  eld of investigation, with much knowledge gained but 
many questions still left to answer. Th  e complexity and 
number of factors involved in disease make it diﬃ   cult to 
derive a clear step-by-step pathogenic pathway. A 
summary of proposed pathogenic mechanisms is illus-
trated in Figure 1. Autoanti  bodies and ICs are important 
ﬁ  rst mediators that are required for disease expression in 
human disease. Deposition of ICs, however, is not 
suﬃ     cient for disease expression, as numerous studies 
report lack of prolifera  tive disease despite signiﬁ  cant 
IgG/IC deposition in glomeruli. Downstream mediators 
are blocked in these pharmacologic/genetic studies, 
inhibiting disease activity without impacting IC deposi-
tion. Complement, TLRs and FcγRs play an ampliﬁ  cation 
role in the initiation and propagation of disease. IC 
deposition with complement, TLR and/or FcγR 
activation stimulates intrinsic immune active glomerular 
cells to release inﬂ  ammatory cytokines and chemoattrac-
tant chemokines, resulting in the inﬂ  ux of the spectrum 
of inﬂ   ammatory cells. Th  e end mediators of disease 
appear to be the reactive intermediates produced by both 
inﬂ   ammatory cells and intrinsic glomerular cells. 
Although tissue repair post inﬂ  ammatory injury is also 
probably a key prognostic process, very little is known 
regarding factors involved in tissue repair. Th  ese  multiple 
mediators provide a host of targets for therapeutic 
intervention. Only 50% of patients respond to current 
standards of therapy. Clearly there is room for improve-
ment, but no one therapy will probably be eﬀ  ective in 
most patients. Determining which pathway is key to a 
given patient is the challenge for the immediate future, as 
well as developing safe mechanisms for blocking these 
pathways.
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